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http:WHAT THIS PAPER ADDS
Current selection criteria for intervention in carotid disease are still determined by symptomatology and the
degree of luminal stenosis. This strategy has not been effective in identifying a high-risk asymptomatic subgroup,
and much effort has been directed at identifying asymptomatic but vulnerable plaques. This work describes the
development of a dual targeting strategy directly reporting arterial endothelial activation in human plaque tissue
by using antibody-conjugated SPIO particles as MRI probes for inﬂammation. These MRI probes could potentially
provide clinicians with a novel imaging tool for characterization of atherosclerosis at a molecular level, thereby
permitting accurate risk stratiﬁcation in carotid disease.Objectives: Identiﬁcation of those patients with high-risk asymptomatic carotid plaques remains an elusive but
essential step in stroke prevention. Inﬂammation is a key process in plaque destabilization and the propensity of
atherosclerotic lesions to cause clinical sequelae. There is currently no clinical imaging technique available to
assess the degree of inﬂammation associated with plaques. This study aims at visualizing and characterizing
atherosclerosis using antibody-conjugated superparamagnetic iron oxide (SPIO) particles as an MRI probe to
assess inﬂammation in human atherosclerotic plaques.
Methods: Atherosclerotic plaques were collected from 20 consecutive patients (n ¼ 10 from symptomatic
patients, n ¼ 10 from asymptomatic patients) undergoing carotid endarterectomy (CEA) for extracranial high-
grade internal carotid artery (ICA) stenosis (>70% luminal narrowing). Inﬂammatory markers on human
atherosclerotic plaques were detected and characterized by ex vivo magnetic resonance imaging (MRI) using anti-
VCAM-1 antibody and anti-E-selectin antibody-conjugated SPIO with conﬁrmatory immunohistochemistry.
Results: Inﬂammation associated with human ex vivo atherosclerotic plaques could be imaged using dual
antibody-conjugated SPIO by MRI. Symptomatic plaques could be distinguished from asymptomatic ones by the
degree of inﬂammation, and the MR contrast effect was signiﬁcantly correlated with the degree of plaque
inﬂammation (r ¼ .64, p < .001). The asymptomatic plaque population exhibited heterogeneity in terms of
inﬂammation. The dual-targeted SPIO-induced MR signal not only tracked closely with endothelial activation (i.e.
endothelial expression of VCAM-1 and E-selectin), but also reﬂected the macrophage burden within plaque
lesions, offering a potential imaging tool for quantitative MRI of inﬂammatory activity in atherosclerosis.
Conclusions: These functional molecular MRI probes constitute a novel imaging tool for ex vivo characterization
of atherosclerosis at a molecular level. Further development and translation into the clinical arena will facilitate
more accurate risk stratiﬁcation in carotid artery disease in the future.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid endarterectomy (CEA) for symptomatic internal
carotid artery (ICA) atherosclerotic lesions is a well-
recognized intervention in stroke prevention. The case for
intervention in asymptomatic lesions has become more
controversial with the development of better medical pre-
ventative treatment, and with an annual stroke risk of 1e
2%1 for asymptomatic threshold disease it is more difﬁcult
to justify surgery or stenting. Nonetheless, asymptomatic
benign atherosclerotic lesions do go on to become unstable
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reliable methodology to identify these lesions. Promising
non-invasive imaging techniques, such as contrast-
enhanced ultrasound, high-resolution magnetic resonance
imaging (MRI), and co-registered positron emission to-
mography with computed tomography (CT) and MRI are
currently in development in order to interrogate plaque
vulnerability in vivo. High-resolution MRI has emerged as a
leading non-invasive imaging modality for assessing
atherosclerosis, because of its excellent spatial resolution at
a submillimetre level, soft-tissue contrast, and high signal-
to-noise ratio. The signiﬁcant advantage of MRI is the
ability to acquire and combine multiple different contrast
weightings to characterize tissue composition within the
vessel wall, resulting in the quantiﬁcation of the main pla-
que components such as intraplaque haemorrhage, lipid-
rich necrotic core, calciﬁcation, and surface disruption.2
There are two types of MRI contrast agents, namely para-
magnetic and superparamagnetic, which increase sensitivity
and facilitate diagnosis by shortening T1 and T2 relaxation
times respectively. In contrast to paramagnetic contrast
agents (gadolinium) that create hyperintense signals (“pos-
itive” contrast) in T1-weighted images, superparamagnetic
contrast agents shorten the transverse T2 and T2* relaxation
times, resulting in hypointense signals that appear black on
T2- and T2*-weighted MR images (“negative” contrast).3
These superparamagnetic agents are based on iron oxide
particles, which are composed of a core of iron oxides,
coated by a biocompatible inert polymer, usually dextran.4
However, to fully capture the diagnostic potential of MRI
requires imaging at molecular and cellular levels. Molecular
MRI comprises “passive” and “active” imaging strategies.
Ultrasmall superparamagnetic particles of iron oxide (USPIO)
have been used as passive contrast agents to identify plaque
macrophages as surrogate markers of plaque inﬂammation
in the assessment of atherosclerosis in human and animal
models.5e7 “Active” molecular imaging involves direct
reporting of speciﬁc molecular events, which mandates the
use of a speciﬁc targeting system. Target speciﬁcity of
contrast agents can be customized through conjugation of a
variety of targeting ligands, such as monoclonal antibodies,
antibody fragments (Fab), peptides or sugars, to functional
groups on the surface of iron oxide particles.8,9
Inﬂammation is a key driver of plaque instability. Macro-
phages play a critical role in promoting ﬁbrous cap degra-
dation and plaque destabilization, converting chronic stable
atherosclerotic lesions into acute unstable lesions with the
potential for thromboembolism. Monocyte recruitment into
vascular tissues is promoted by the overexpression of
adhesion molecules, such as vascular cell adhesion molecule-
1 (VCAM-1; CD106), E-selectin (CD62E), and P-selectin
(CD62P), on the activated endothelium.10 The monocytee
endothelial binding mechanism represents an opportunity to
exploit both cell adhesion molecules and selectins on the
activated endothelium as targets to directly report arterial
endothelial activation and inﬂammation. A dual targeting
strategy directed at E-selectin and VCAM-1 using antibody-
conjugated superparamagnetic particles of iron oxide(SPIO) to act as a contrast agent in order to render activated
arterial endothelium MR visible has been developed.
In this article the detection and characterization of E-
selectin and VCAM-1 on excised human carotid plaques
using antibody-conjugated SPIO and immunohistochemistry
is described. The extent to which antibody-conjugated SPIO-
induced MR signal tracks endothelial activation across a
range of atherosclerotic lesion complexities in humans by
ex vivo MRI is evaluated. It was hypothesized that symp-
tomatic carotid plaques could be discriminated from
asymptomatic ones predicated on the degree of inﬂamma-
tion detected, and additionally sought to determine whether
asymptomatic plaques could be distinguished based on the
degree of inﬂammation exhibited using these MRI probes.MATERIALS AND METHODS
Study population
Atherosclerotic plaques were collected from 20 consecutive
patients (n ¼ 10 from symptomatic patients, n ¼ 10 from
asymptomatic patients) undergoing CEA for extracranial
high-grade ICA stenosis of 70% or greater, using the North
American Symptomatic Carotid Endarterectomy Trial criteria.
Symptomatic patients were deﬁned as those who had a his-
tory of recent (less than 4 months before enrolment) tran-
sient retinal or cerebral symptoms or ischaemic stroke
attributable to the high-grade ICA lesion.11 Asymptomatic
patients were deﬁned as those who had no history or only
remote (more than 4 months) ischaemic symptoms. The
symptomatic group had presented with cerebrovascular
transient ischaemic attacks (n¼ 8) or ischaemic stroke (n¼ 2)
within the preceding 4 months. All other specimens were
collected from 10 clinically asymptomatic patients exhibiting
ipsilateral ICA stenosis of >70% on serial ultrasound duplex.
The degree of ICA stenosiswas established in two consecutive
ultrasound duplex before surgery in all cases, and additionally
conﬁrmed by either CT angiography (CTA) orMR angiography
(MRA). Preoperatively all patients underwent neurological
evaluation. Macroscopically normal specimens adjacent to
endarterectomized plaques were harvested from patients
(n ¼ 2) undergoing femoral endarterectomy to serve as
controls forMRI and histology.The studywas conducted from
2009 to 2012 and was approved by the local ethics commit-
tee.Written informed consentwas obtained fromall patients.Tissue collection
All patients underwent CEA in the regional vascular unit at
St Mary’s Hospital, London, UK. The median duration of
patients undergoing CEA after symptom onset was 9 (range
5e35) days. At operation the carotid artery bifurcation was
endarterectomized with the intention to remove the whole
plaque intact. The excised plaque sample consisted of in-
tima and inner medial layers of the artery. Thereafter the
plaque was rinsed with phosphate-buffered saline (PBS) and
cut into ﬁve sections, each of which was further subdivided
into two smaller adjacent sections (Fig. 1). Great care was
taken to prevent plaque disintegration during division of the
Figure 2. Experimental design of ex vivo human plaque stage. The in
biotinylated antibodies, which were in turn bound to the strepta
Concomitant immunohistochemistry was performed.
Figure 1. Carotid endarterectomy (CEA) specimen cut into sec-
tions. At CEA operation, the carotid artery bifurcation was
endarterectomized with the aim of removing the whole plaque
intact. The plaque was cut into ﬁve sections, each of which was
further subdivided into two smaller adjacent sections. One adja-
cent section was used for magnetic resonance imaging detection
and characterization of inﬂammatory markers, whilst the other
adjacent section was used for immunohistochemistry.
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sections were marked and recorded. One adjacent section
was ﬁxed in 4% paraformaldehyde (PFA) at 4 C for MRI
detection and characterization of inﬂammatory markers,
while the other adjacent section was ﬁxed in formalin and
embedded in parafﬁn blocks for immunohistochemistry.
Concomitant immunohistochemistry was performed to
correlate MRI data.Detection, characterization, and imaging of inﬂammatory
markers on human carotid plaques by biotinylated
antibody-conjugated streptavidin microbeads
Following ﬁxation in 4% PFA, plaque sections were rinsed in
PBS. They were incubated with 2% horse serum at room
temperature for 1 hour to block non-speciﬁc binding of anti-
bodies. Plaque sections were then incubatedwith biotinylated
mouse anti-human E-selectin monoclonal antibody (dilution
10 mg/mL, R&D Systems, Abingdon, UK) and biotinylated
mouse anti-human VCAM-1 monoclonal antibody (dilution
10 mg/mL, GenWay Biotech, San Diego, USA) for 20minutes at
room temperature. Plaque sections were washed twice to
remove unbound biotinylated antibodies by incubating with
labelling buffer composed of PBS, supplemented with 2 mM
EDTA at 4 C for 10minutes.Tomake the plaques become “MR
visible”, they were incubated in streptavidin microbeads
(Miltenyi Biotec Ltd, Surrey, UK), that ismagnetic beads (50 nm
diameter SPIO) conjugated to streptavidin, diluted in labelling
buffer (dilution 1:10) at 4 C for 15 minutes (Fig. 2).Ex vivo MRI of human carotid plaques
The carotid plaque from each patient was divided into ﬁve
smaller sections giving symptomatic (n ¼ 50), asymptomaticﬂammatory markers on human carotid plaque were detected by
vidin microbeads, thereby making these plaques “MR visible”.
Figure 3. Human carotid plaque sections embedded in agarose block. A tube of microbeads was also embedded in the agarose block to act
as positive control.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 5 p. 462e469 May/2014 465(n ¼ 50), control femoral artery sections (n ¼ 10), together
with three controls (symptomatic carotid plaque incubated
with biotinylated non-immune IgG antibodies and
microbeads, symptomatic carotid plaque, and streptavidin
microbeads). All were embedded in 2% agarose (Fig. 3).
Ex vivo MRI of human carotid plaques was performed using
a 9.4-Tesla, horizontal bore scanner (Varian Inc., Palo Alto,
CA, USA) running VnmrJ 2.3A software. The sample was
placed in a quadrature birdcage coil (40 mm internal
diameter). T2 spin echo sequence parameters are listed in
the Supplementary Material.
Quantitative MR image analysis
MR images were analysed by ImageJ 1.43r software (Na-
tional Institutes of Health, http://rsb.info.nih.gov/ij/index.
html). The contours of each plaque section on the MR im-
age were delineated manually and independently by two
observers and deﬁned as the region of interest (ROI). The
signal within the ROI (plaque signal) was measured using
ImageJ 1.43r software. The contrast effect in each plaque
section was quantiﬁed by T2 value, which was calculated
using GraphPad Prism 5 software (GraphPad software Inc.,
San Diego, USA).
Microscopy and quantiﬁcation of immunostaining
Wide-ﬁeld microscopy was performed with a Zeiss Axiovert
200 inverted microscope. The area of positive staining of
VCAM-1, E-selectin, CD68 (macrophages), CD31 (endothelial
cells), and Perls’ stain (intralesional iron) in each plaque
section was objectively quantiﬁed using Volocity 5.5 image
analysis software (PerkinElmer, Boston, MA, USA). The
stained area of Perls’ (iron) and CD68 (macrophages) was
quantiﬁed as a percentage of the total lesion area.12 CD31 is
commonly used to demonstrate the presence of endothelial
cells. Hence the area of CD31 expression was considered asa total area of intact endothelium. Quantitative stereologi-
cal analysis of VCAM-1 and E-selectin endothelial expression
was related to CD31 staining in endothelium and calculated
as
VCAM-1/E-selectin expression on endothelial cells (%) ¼ [Area (x)/Area
(CD31)]  100% where area (x) is the area of VCAM-1 or E-selectin
expression in the endothelium and area (CD31) is the area of CD31
expression in the endothelium.13Details concerning immunohistochemistry, intra/
interobserver variability in the quantiﬁcation of the
contrast effect are found in the Supplementary Data
Statistical methods. To assess differences in categorical
variables in patient clinical characteristics, the Fisher exact
test (two-tailed) was used. The relationship between the
mean macrophage content and MR contrast effect quanti-
ﬁed by mean 1/T2 of the whole plaque per patient was
assessed by Spearman’s correlation. Further, the whole
plaque has signal change assessed in ﬁve smaller plaque
sections in order to minimize the chance of a focal signal
change being “lost” in a mean signal change for the whole
plaque. However, each of these plaque sections cannot be
examined as an independent observation as the signal in
one section will affect that in its adjacent section. To reduce
potential statistical error, a complex repeated measures
modelling was chosen to represent true variances in section
data, thereby yielding the degrees of freedom to the correct
level. The strength of the relationship between histological
marker data (expression of VCAM-1, E-selectin, CD68 and
Perls’ iron stain) and MR image data in each of the ﬁve
carotid plaque sections per patient was assessed using
correlation and regression analysis. Since data were
collected on ﬁve sections per patient, repeated measures
regression model were ﬁtted by using MR image data as
466 J.M.S. Chan et al.response variables and histological marker data as predictor
variables, taking the symptom status of patient into
account.
Repeated measures analysis of variance (ANOVA) was
performed using general linear model function in Statistical
Analysis System 9.1 software (SAS Institute, Inc, Cary, NC,
USA). A value of p < .05 was considered statistically sig-
niﬁcant. Intraobserver and interobserver variability in T2
values were analysed using a BlandeAltman plot.
RESULTS
Baseline demographics
Baseline demographics and clinical risk factors were similar
in both symptomatic and asymptomatic patient groups
(Table 1).Relationship between plaque macrophage content and MR
contrast effect
This study showed that the degree of inﬂammation asso-
ciated with human atherosclerotic plaques could be imaged
using dual antibody-conjugated SPIO by ex vivo MRI. Fig. 4
demonstrates a spectrum of MR images ranging from
phenotypically symptomatic inﬂamed plaques, appearing
darkest, followed by the asymptomatic plaques, to control
femoral artery and negative controls (symptomatic plaque
only and symptomatic plaque with IgG and microbeads),
appearing brightest. Macrophage content in plaque was
used as an index of plaque inﬂammation. Plaques wereTable 1. Patient clinical characteristics.
Variable Symptomatic Asymptomatic p
Median age (range) 73 (67e76) 72 (66e77) 0.7039b
Gender, male/female 7/3 6/4 1.0000
TIA, no. 8 0 0.0007a
Stroke, no. 2 0 0.4737
Ischaemic heart
disease, no.
4 5 1.0000
Diabetes mellitus, no. 2 3 1.0000
Hypertension, no. 7 7 1.0000
Hypercholesterolaemia,
no.
7 8 1.0000
Smoking, no. 4 6 0.6563
Medications:
statin, no.
6 8 0.6285
Medications:
antihypertensives, no.
7 7 1.0000
Medications:
aspirin, no.
5 7 0.6499
Medications:
Clopidogrel, no.
4 0 0.0867
Medications:
NSAIDs, no.
2 1 1.0000
Note. NSAIDs, non-steroidal anti-inﬂammatory drugs; TIA,
transient ischaemic attack.
a None of these characteristics differ signiﬁcantly other than that
for TIA, as determined by the Fisher exact test.
b No signiﬁcant difference in age was found between the two
patient groups, as determined by the Mann-Whitney U test.deﬁned as inﬂamed if there was greater than 5% of
macrophage staining in the total lesion area. Importantly, it
was possible to observe a degree of heterogeneity in the
asymptomatic plaque population based on the varying de-
gree of inﬂammation, with inﬂamed plaques appearing
darker than non-inﬂamed ones. Consistent with the MR
images, the concomitant immunohistochemistry for CD68
(macrophages) was observed to be the most abundant on
phenotypically symptomatic inﬂamed plaques, followed by
the inﬂamed asymptomatic ones, then the non-inﬂamed
asymptomatic ones and the least for the control femoral
artery sections.
To quantify these observations, the mean 1/T2 value (MR
contrast effect) of whole plaque was calculated. Fig. 5
demonstrates that the mean macrophage content (index
of plaque inﬂammation) is signiﬁcantly correlated with the
mean 1/T2 of the whole plaque per patient (r ¼ .64,
p < .001). Consistent with the MRI results, the symptomatic
plaques (in red) with the greater level of inﬂammation
produced a higher 1/T2 value and appeared darker, fol-
lowed by the inﬂamed asymptomatic plaques (in orange),
then the non-inﬂamed plaques (in yellow).
Relationship between expression of histological markers
and MR contrast effect
Taking the symptom status of each patient into account, the
strength of the relationship between histological marker data
(expression of VCAM-1, E-selectin, CD68, and Perls’ iron
stain) and the MR contrast effect in each of the ﬁve carotid
plaque sections per patient was assessed. The ﬁtted regres-
sion model with endothelial expression of VCAM-1 in carotid
plaque sections as predictors and 1/T2 as response variable
controlling for symptom status of patient reported R2 ¼ .79,
indicating that 79% of the variation in 1/T2 is ﬁtted by the
endothelial VCAM-1 expression in the plaque sections. The
overall regression model was found to be statistically signif-
icant, F(9, 90)¼ 37.93, p< .01. The t test demonstrated that
the estimated regression model parameter for endothelial
VCAM-1 expression was found to be statistically signiﬁcant
(b¼ 0.00224, t (1)¼ 7.317, p< .001). Therefore endothelial
VCAM-1 expression in carotid plaque sections and 1/T2 is
signiﬁcantly strongly correlated. Similarly, endothelial
expression of E-selectin in carotid plaque sections and 1/T2
was also signiﬁcantly strongly correlated (R2 ¼ 0.82, F(9,
90)¼ 46.71, p< .01), (b¼ 0.00339, t (1)¼ 7.48, p< .001). In
comparison, CD68 expression in carotid plaque sections and
1/T2 was statistically signiﬁcant, yet moderately correlated
(R2 ¼ 0.5687, F(4, 105) ¼ 34.61, p < .001; b ¼ 0.001, t
(1)¼ 5.13, p< .0001).The effect of intralesional iron content,
indicative of past intraplaque haemorrhage, as visualized by
Perls’ stain in carotid plaque sections on 1/T2 was not sta-
tistically signiﬁcant.
Synergistic relationship of E-selectin and VCAM-1
expression on 1/T2
Repeated measures ANOVA was performed to test the
signiﬁcance of the effect of VCAM-1 and E-selectin
Figure 4. Spectrum of magnetic resonance (MR) images and histological images of phenotypically symptomatic plaques, asymptomatic
plaques and control femoral artery. The spectrum of MR images in the upper row range from phenotypically symptomatic inﬂamed
plaques, appearing darkest, followed by the asymptomatic plaques, to control femoral artery and negative controls (symptomatic plaque
only and symptomatic plaque with IgG and microbeads), appearing brightest. Importantly, a degree of heterogeneity in the asymptomatic
plaque population is detected, with inﬂamed plaques appearing darker than non-inﬂamed ones. Consistent with the MR images, the
concomitant immunohistochemistry for CD68 (macrophages as indicated by brown stain) in the lower row is observed to be the most
abundant on phenotypically symptomatic inﬂamed plaques, followed by the inﬂamed asymptomatic ones, then the non-inﬂamed
asymptomatic ones and the least for the control femoral artery sections.
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of the ﬁve carotid plaque sections per patient. VCAM-1
expression and E-selectin expression explained 94.08% of
the variation in 1/T2 in carotid plaque sections
(R2 ¼ 0.9408) and was statistically signiﬁcant (F(1,
103) ¼ 272.64, p < .001; b ¼ 0.00015, t (1) ¼ 8.96,
p < .01). Compared with using E-selectin or VCAM-1
expression alone, there was an increase of 12% and 15%
respectively in the explanatory power by using E-selectinFigure 5. The relationship between intraplaque inﬂammation and magn
(index of plaque inﬂammation) is signiﬁcantly correlated with the mean
p < .001). Consistent with the MRI results, the symptomatic plaques (in
value and appear darker; followed by the inﬂamed asymptomatic plaqand VCAM-1 expression together. Therefore it is concluded
that there is a signiﬁcant synergistic relationship between
VCAM-1 and E-selectin endothelial expression on 1/T2.DISCUSSION
A biological dual-targeting contrast strategy directly
reporting the arterial endothelial activation attracting the
monocytes in human plaque tissue has been developed inetic resonance (MR) contrast effect. The mean macrophage content
1/T2 (MR contrast effect) of the whole plaque per patient (r ¼ .64,
red) with the greater level of inﬂammation produce a higher 1/T2
ues (in orange), then the non-inﬂamed plaques (in yellow).
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prognostic information to luminal stenosis alone. It has
been possible to discriminate symptomatic plaques from
asymptomatic ones predicated on the degree of inﬂam-
mation, and, more importantly, inﬂamed plaques from the
non-inﬂamed ones within the asymptomatic plaque popu-
lation by ex vivo MRI. This study showed that the mean 1/
T2 value of the whole plaque was signiﬁcantly correlated
with plaque inﬂammation. Supported by previous post-
mortem and atherectomy studies, increased expression of
VCAM-1, E-selectin, and P-selectin was known to correlate
with a high density of macrophages and T lymphocytes in
the inﬂamed coronary and carotid plaques.14 These data
suggest that higher levels of VCAM-1 and E-selectin endo-
thelial expression from the inﬂamed plaques resulted in
greater binding of antibody-conjugated microbeads to the
endothelial cells, producing a greater signal loss in T2 spin
echo sequence and greater 1/T2 value.
This was conﬁrmed by further analysis using repeated
measures modelling to assess the strength of the relation-
ship between histological marker data and MR contrast
effect in each of the ﬁve carotid plaque sections per patient.
As previously described,15 this complex statistical model
aims to provide a more robust analysis of the data than
simple paired analysis. In this model, a stronger correlation
between endothelial expression of VCAM-1 and E-selectin
with 1/T2 was demonstrated than that of CD68 with 1/T2,
suggesting that the antibody-conjugated iron particles pre-
dominantly targeted activated endothelial cells rather than
macrophages. The dual-targeted SPIO-induced MR signal
not only tracked closely with endothelial activation but
unsurprisingly also reﬂected the macrophage burden within
plaque lesion, suggesting that the degree of inﬂammation
and endothelial activation correlated with the number of
plaque-based macrophages. The results were consistent
with the role of increased endothelial expression of adhe-
sion molecules in promoting monocyte recruitment into
vascular tissues.10,16 The present results afﬁrm that the MRI
combined with the dual-targeted SPIO approach can
potentially offer a novel imaging tool for quantitative
assessment of inﬂammation across a range of atheroscle-
rotic lesions complexities in the future.
Furthermore, this study has utilized selectin-mediated
monocyte rolling and VCAM-1-mediated ﬁrm adhesion
mechanisms to develop the antibody-conjugated SPIO. This
work demonstrated a signiﬁcant synergistic relationship
between VCAM-1 and E-selectin endothelial expression on
1/T2 value, supporting a synergistically augmented binding
of dual antibody-conjugated iron particles to atheroscle-
rosis, compared with either in isolation. Although this is
ex vivo work, it is the ﬁrst study to demonstrate the syn-
ergistically augmented binding effect of the dual antibody-
conjugated iron particles on human atherosclerotic plaques.Limitations and future work
The very high binding afﬁnity of biotin with streptavidin has
led to the use of this binding complex in a wide variety ofin vitro and in vivo applications. However, the signiﬁcant
level of endogenous biotin present in serum and the slow
dissociation of the biotinestreptavidin complex can pose a
potential limitation of the translation of biotinylated
antibody-conjugated streptavidin microbeads in clinical
diagnostic and therapeutic applications. Moreover, the size
of the SPIO was 50 nm in diameter. Compared with mi-
croparticles of iron oxide, SPIO can only convey a relatively
small payload of iron, limiting its effect on local magnetic
ﬁeld homogeneity, and therefore compromising the
contrast sensitivity. The substantial contrast effect and
sensitivity of the dual antibody-conjugated SPIO demon-
strated in this ex vivo study could be undermined when
being translated to the in vivo condition. The small particle
size permits SPIO to enter atherosclerotic plaques, poten-
tially compromising the speciﬁcity of these particles for
molecular targets expressed on vascular endothelium.
However, the short incubation period of SPIO with plaque
sections limits their passive diffusion into plaques. This was
supported by the minimal signal loss on the negative con-
trol, symptomatic plaque incubated with non-immune IgG
and microbeads, suggesting that non-speciﬁc binding or
diffusion of SPIO to plaque sections was minimal (Fig. 4).
Future work will use iron oxide particles of larger size in
order to enhance their sensitivity to achieve in vivo
detection of low-abundance endothelial molecular targets.
The streptavidinebiotin link between the biotinylated pri-
mary antibody and streptavidin microbeads will need to be
replaced by a direct conjugation of antibodies to the iron
oxide particles to bring the methodology a step closer to a
practical clinical application.
CONCLUSION
Using the dual antibody-conjugated SPIO, the degree of
inﬂammation associatedwith human atherosclerotic plaques
has been imaged by ex vivo MRI. More importantly, the
potentially high-risk inﬂamed plaques have been identiﬁed
from the non-inﬂamed ones within the asymptomatic plaque
population. The dual-targeted SPIO-induced MR signal not
only tracked closely with endothelial activation (i.e. endo-
thelial expression of VCAM-1 and E-selectin), but also re-
ﬂected the macrophage burden within plaque lesions,
offering a potential imaging tool for quantitative MRI of in-
ﬂammatory activity in atherosclerosis. Moreover, this study
has demonstrated the synergistically augmented binding
effect of the dual antibody-conjugated SPIO on human
atherosclerotic plaques. These functional molecular MRI
probes potentially provide clinicians with a novel imaging
tool for in vivo characterization of atherosclerosis at a mo-
lecular level, thereby permitting more accurate risk stratiﬁ-
cation in carotid artery disease and optimizing resource
allocation to target the high-risk cohorts in the future.
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